Substituted oxazolidinones for combinational therapy
View Patent ↗The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.
1. A combination comprising
A) at least one compound of the formula (I)
in which
R 1 is 2-thiophene which is substituted in position 5 by a radical selected from chlorine, bromine, methyl and trifluoromethyl,
R 2 is D-A-:
where:
the radical “A” is phenylene;
the radical “D” is a saturated 6-membered heterocycle which is linked via a nitrogen atom to “A”, and
which has a carbonyl group directly adjacent to the linking nitrogen atom, and
in which a ring carbon member may be replaced by a heteroatom selected from the series S, N and O;
where
the group “A” defined above may optionally be substituted once or twice in the meta position relative to the linkage to the oxazolidinone by a radical selected from fluorine, chlorine, nitro, amino, trifluoromethyl, methyl and cyano, and
R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are hydrogen, and
B) a platelet aggregation inhibitor.
2. The combination as claimed in claim 1 , wherein the compound A) is 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl) -2-thiophenecarboxamide of the formula
3. The combination as claimed in claim 1 , wherein the platelet aggregation inhibitor is a clopidogrel.
4. A pharmaceutical composition comprising at least one combination as claimed in claims 1 , 2 or 3 and one or more pharmacologically suitable excipients and/or carriers.